(Q44355510)

English

Phase I, randomized, double-blind, placebo-controlled, single-dose escalation study of the recombinant factor VIIa variant BAY 86-6150 in hemophilia

scientific article published in May 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

Phase I, randomized, double-blind, placebo-controlled, single-dose escalation study of the recombinant factor VIIa variant BAY 86-6150 in hemophilia (English)

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

0 references

1 reference

based on heuristic

inferred from title

author name string

J N Mahlangu

1

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

M J Coetzee

2

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

M Laffan

3

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

J Windyga

4

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

T T Yee

5

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

J Schroeder

6

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

J Haaning

7

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

J E Siegel

8

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

G Lemm

9

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

1 May 2012

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

Journal of Thrombosis and Haemostasis

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

10

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

5

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

773-780

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

A randomized, double-blind comparison of two dosage levels of recombinant factor VIIa in the treatment of joint, muscle and mucocutaneous haemorrhages in persons with haemophilia A and B, with and without inhibitors. rFVIIa Study Group

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2012.04667.X

21 January 2018

Dose effect and efficacy of rFVIIa in the treatment of haemophilia patients with inhibitors: analysis from the Hemophilia and Thrombosis Research Society Registry

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2012.04667.X

21 January 2018

A prospective randomized trial of high and standard dosages of recombinant factor VIIa for treatment of hemarthroses in hemophiliacs with inhibitors

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2012.04667.X

21 January 2018

How factor VIIa works in hemophilia

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2012.04667.X

21 January 2018

Mechanism of factor VIIa-dependent coagulation in hemophilia blood

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2012.04667.X

21 January 2018

Pharmacokinetics of recombinant activated factor VII (rFVIIa).

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2012.04667.X

21 January 2018

Platelet binding and activity of recombinant factor VIIa

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2012.04667.X

21 January 2018

Platelet activity of high-dose factor VIIa is independent of tissue factor

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2012.04667.X

21 January 2018

The use of recombinant factor VIIa in the treatment of bleeding disorders.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2012.04667.X

21 January 2018

Rational design of coagulation factor VIIa variants with substantially increased intrinsic activity.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2012.04667.X

21 January 2018

A variant of recombinant factor VIIa with enhanced procoagulant and antifibrinolytic activities in an in vitro model of hemophilia

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2012.04667.X

21 January 2018

Improved hemostasis with superactive analogs of factor VIIa in a mouse model of hemophilia A.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2012.04667.X

21 January 2018

Glycoengineering: the effect of glycosylation on the properties of therapeutic proteins

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2012.04667.X

21 January 2018

Treatment and outcome of acquired haemophilia A with a standard conventional regimen in a cohort without associated conditions

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2012.04667.X

21 January 2018

Identifiers

10.1111/J.1538-7836.2012.04667.X

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44355510&oldid=2019727474"